Thomas Adams - Jun 10, 2021 Form 4 Insider Report for Cardiff Oncology, Inc. (CRDF)

Role
Former Director
Signature
/s/ Thomas Adams
Stock symbol
CRDF
Transactions as of
Jun 10, 2021
Transactions value $
$0
Form type
4
Date filed
6/14/2021, 04:10 PM
Previous filing
May 20, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRDF Stock Options Other $0 +272 +0.06% $0.00 478K Jun 10, 2021 Common Stock 272 $447.84 Direct F1, F2
transaction CRDF Stock Options Other $0 +223 +0.05% $0.00 478K Jun 10, 2021 Common Stock 223 $7.18 Direct F1
transaction CRDF Stock Options Other $0 +223 +0.05% $0.00 478K Jun 10, 2021 Common Stock 223 $5.18 Direct F1
transaction CRDF Stock Options Other $0 +530 +0.11% $0.00 478K Jun 10, 2021 Common Stock 530 $51.84 Direct F1
transaction CRDF Stock Options Other $0 +755 +0.16% $0.00 478K Jun 10, 2021 Common Stock 755 $21.60 Direct F1
transaction CRDF Stock Options Other $0 +298K +166.15% $0.00 478K Jun 10, 2021 Common Stock 298K $2.48 Direct F1, F3
transaction CRDF Stock Options Other $0 +173K +56.82% $0.00 478K Jun 10, 2021 Common Stock 173K $2.60 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Expiration date of the stock options was extended to June 10, 2023.
F2 7,338 of the stock options vest immediately. 4,077 of the stock options vest on each of 2/25/2015 and 2016 and 4,076 of the stock options vest on 2/25/2017.
F3 In connection with the Reporting Person's separation agreement dated December 21, 2020, the Compensation Committee accelerated the vesting of such stock options to December 29, 2020.